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ABSTRACT
Background
Malaria and hypertension are major causes of maternal mortality in tropical countries,
especially during first pregnancies, but evidence for a relationship between these syndromes is
contradictory.
Methods and Findings
In a cross-sectional survey of Tanzanian parturients, the rate of hypertension was similar in
placental malaria (PM)-positive (11/85 ¼ 13%) and PM-negative (73/602 ¼ 12%) individuals.
However,wefoundthatPMwasassociatedwithhypertensioninfirst-timemothersaged18–20y
but not other mothers. Hypertension was also associated with histologic features of chronic
malaria, which is common in first-time mothers. Levels of soluble vascular endothelial growth
factor receptor 1 (sVEGFR1), a preeclampsia biomarker, were elevated in first-time mothers with
either PM, hypertension, or both, but levels were not elevated in other mothers with these
conditions.Infirst-timemotherswithPM,theinflammatorymediatorvascularendothelialgrowth
factor (VEGF) was localized to maternal macrophages in the placenta, while sVEGFR1, its soluble
inhibitor, was localized to the fetal trophoblast.
Conclusions
The data suggest that maternal–fetal conflict involving the VEGF pathway occurs during PM,
and that sVEGFR1 may be involved in the relationship between chronic PM and hypertension in
first-time mothers. Because placental inflammation causes poor fetal outcomes, we
hypothesize that fetal mechanisms that promote sVEGFR1 expression may be under selective
pressure during first pregnancies in malaria-endemic areas.
The Editors’ Summary of this article follows the references.
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Placental malaria (PM) caused by Plasmodium falciparum
preferentially affects ﬁrst-time mothers: rates of up to 70%
occur in regions of sub-Saharan Africa, where low birth
weight due to PM is estimated to cause 200,000 infant deaths
each year. Among the dozens of malaria parasite species that
infect mammals, only P. falciparum is known to sequester in
the placenta during naturally occurring infections [1]. During
PM, infected erythrocytes (IE) adhere to chondroitin sulfate A
and sequester in the intervillous spaces of the placenta [2].
Over successive pregnancies, women acquire antibodies that
block IE adherence [3]. First-time mothers lack these anti-
bodies, and therefore often experience dense parasitemias
and intense inﬂammatory responses.
Hypertensive disorders of pregnancy occur primarily in
humans, and are estimated to cause 10%–15% of maternal
deaths [4]. Preeclampsia, deﬁned by hypertension and
proteinuria, is the most well-described disorder [5]. Like
PM, preeclampsia is more common in ﬁrst-time mothers,
but for unknown reasons. The pathogenesis of preeclampsia
is obscure, although abnormal placentation is currently
considered among the more plausible hypotheses. Recent
ﬁndings and theories reviewed elsewhere [5–8] have vari-
ously imputed roles for systemic inﬂammation, abnormal-
ities in cardiovascular adaptation to pregnancy, agonistic
autoantibodies to the angiotensin receptor, and aberrations
in calcium metabolism, as well as anti-angiogenic factors
(discussed further below). Fetal mechanisms that cause
hypertension have been proposed to have evolved as a
result of maternal–fetal conﬂict over nutrient allocation
[9,10].
Malaria is well known to decrease blood pressure in non-
pregnant individuals, but the relationship between PM and
blood pressure is not clear [11]. During the 1935 malaria
epidemic in Sri Lanka, the obstetrician Wickramasuriya
described an ‘‘‘epidemic’ of ...toxaemic pregnancies follow-
ing in the wake of the malaria epidemic’’, with hypertension
in 20%, albuminuria in 40%, edema in 50%, and death in
13% of 357 infected women [12]. In sub-Saharan Africa, the
rates of both preeclampsia and malaria increase during the
cooler rainy season [13–16]; however, in non-malarious areas
preeclampsia may also increase during colder months [17].
Preeclampsia increased the odds of PM in Senegal [15];
however, it was not associated with peripheral parasitemia
[18] or with placental infection by histology [19] in Kenya.
Serum levels of placentally derived soluble vascular
endothelial growth factor receptor 1 (sVEGFR1) are elevated
prior to [20] and during [21] preeclampsia. (sVEGFR1 is also
called soluble fms-like tyrosine kinase 1 [sFlt1].) sVEGFR1
may cause systemic endothelial dysfunction by binding and
sequestering free serum vascular endothelial growth factor
(VEGF) and placental growth factor [20,21]. In earlier studies,
hypertension, proteinuria, and glomerular endotheliosis
developed in rats infected with a recombinant retrovirus
encoding sVEGFR1 [21], and hypertension and proteinuria
developed in cancer patients receiving monoclonal anti-
VEGF therapy [22]. Astrocyte VEGF expression and extrac-
ellular VEGFR1 have been observed in the brain of cerebral
malaria patients [23], but have not been examined in other
malaria syndromes.
Methods
Human Participants
Placental samples and clinical information were provided
by Tanzanian women aged 18–45 y delivering at the Muheza
Designated District Hospital, Muheza, Tanga region. Sample
donors were among those recruited to participate in a birth
cohort study known locally as the Mother-Offspring Malaria
Study. Women provided signed informed consent before
joining the study, and those with chronic debilitating disease
and their children were excluded. Clinical information was
collected by project nurses and assistant medical ofﬁcers on
standardized forms. Study procedures involving human
participants were approved by the International Clinical
Studies Review Committee of the Division of Microbiology
and Infectious Diseases at the US National Institutes of
Health, and ethical clearance was obtained from the Institu-
tional Review Board of Seattle Biomedical Research Institute
and the National Medical Research Coordinating Committee
in Tanzania.
Study Procedures
Hypertension was deﬁned as systolic or diastolic blood
pressure greater than or equal to 140 mm Hg or 90 mm Hg,
respectively. Blood pressure was abstracted from hospital
delivery cards as the maximum measurement recorded
during the delivery hospitalization. Blood pressure measure-
ments were not taken during active labor. Urine protein
assessment was not routinely performed in the hospital.
Immediately prior to delivery, peripheral blood was collected
in citrate phosphate dextrose, and plasma was separated and
frozen at 80 8C. The placenta was collected at delivery, and a
full thickness biopsy from the middle third of the placental
disc was frozen in liquid nitrogen and stored at  80 8C. PM
was detected by microscopy of Giemsa-stained thick and thin
smears of placental blood extracted from placental tissue by
mechanical grinding. Placental parasite density was quanti-
ﬁed as percent IE.
Histopathologic Analysis
Cryosections (5 lm) of placental tissue were Giemsa stained
and assessed by examining greater than 90 60X ﬁelds per
section. Malarial pigment is a brown heme-derived product
that refracts under polarizing light and persists in acellular
ﬁbrinoid in the intervillous space. Pigment deposition in
ﬁbrinoid was quantiﬁed by determining the proportion of
ﬁelds with pigment present. Inﬂammation was qualitatively
s c o r e db yt h ep r e s e n c eo fi n ﬂ a m m a t o r yc e l l si nt h e
intervillous space.
Enzyme-Linked Immunosorbent Assay
Soluble VEGFR1 levels in peripheral plasma were deter-
mined in duplicate by ELISA kit DVR100A (R&D Systems,
Minneapolis, Minnesota, United States). Levels were cor-
rected for dilution volume in anticoagulant, and over-diluted
samples were detected by low potassium concentration as
measured by EasyLyte Plus (Medica, Bedford, Massachusetts,
United States) and excluded.
Quantitative RT-PCR
Total RNA was extracted from frozen cryosections using
RNeasy minikits (Qiagen, Hilden, Germany). RNA quality was
assessed by Agilent 2100 Bioanalyzer (Santa Clara, California,
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was synthesized using Superscript III enzyme (Invitrogen,
Carlsbad, California, United States) and anchored oligodT20
primers. Exon-spanning primers were designed for sVEGFR1:
GGGGAAGAAATCCTCCAGAA(fwd), AGCCTTTTTGTTG-
CAGTGCT(rev), (63-bp product); VEGF (all isoforms):
CCCACTGAGGAGTCCAACAT(fwd), TGCATTCA-
CATTTGTTGTGC(rev), (106-bp product); and cytokeratin 7:
GGCTGAGATCGACAACATCA(fwd), CTTGGCACGAG-
CATCCTT(rev) (103-bp product). Real-time PCR was per-
formed in duplicate using SYBR green master mix and an ABI
Prism 7000 (Applied Biosystems, Foster City, California,
United States) with an annealing temperature of 60 8C.
Threshold cycles (CT) were normalized to CT of KRT7, and t-
tests performed on normalized CT values. Data are presented
as fold-difference from control gene, calculated by
log2
(normalized CT).
Immunostaining
Cryosections (5 lm) were ﬁxed in paraformaldehyde,
blocked in chicken and goat sera (Santa Cruz Biotechnology,
Santa Cruz, California, United States, and Amersham, Little
Chalfont, United Kingdom, respectively), and variously
probed with mouse anti-VEGFR1 extracellular domain
(R&D Systems) at 1:400, which detects both the membrane-
bound and soluble isoforms of VEGFR1, mouse anti-VEGF
clone VG1 (Chemicon, Temecula, California, United States)
at 1:200 and rabbit anti-placental lactogen (Dako, Glostrup,
Denmark) at 1:1,000 dilution. Secondary antibodies included
Alexaﬂuor 488 chicken anti-mouse antibody (Molecular
Probes, Eugene, Oregon, United States) and TRITC goat anti
rabbit antibody (Sigma, St. Louis, Missouri, United States).
DAPI (Sigma) was used to deﬁne nuclear DNA. VEGF was also
visualized using DAB Envisionþkit (Dako), and sections were
counterstained with Giemsa.
Statistical Analysis
Analyses were performed using Statview (SAS Institute,
Cary, North Carolina, United States). Student’s t-test was used
for the analysis of continuous variables. Mann-Whitney test
was used to examine parity and placental pigment deposition.
Peripheral plasma sVEGFR1 concentration and parasite
density (n þ 1) were log-transformed prior to analysis. Odds
ratios were calculated using logistic-regression analysis.
Regression coefﬁcients were calculated using simple regres-
sion analysis. Interactions between variables were determined
using factorial ANOVA. Spearman rank correlation was used
to examine the correlation between sVEGFR1 quantitative
PCR and ELISA measurements.
Results
We examined the relationship between PM and hyper-
tension in northeastern Tanzania. The analysis protocol for
the study was to examine the relationship of demographic
factors including parity and age to hypertension in women
stratiﬁed by PM status. In ﬁrst-time mothers, who are at risk
for both PM and preeclampsia, we examined the histological
features of PM that were associated with hypertension. We
examined the expression of sVEGFR1 in women stratiﬁed by
parity, PM status, and hypertension.
Placental samples and clinical information were provided
by women delivering at the Muheza Designated District
Hospital, in an area of intense malaria transmission [24].
Analyses included 887 women with viable deliveries who
joined the study between September 2002 and March 2005.
Twins were excluded. Blood pressure data were available for
688 women. Women without blood pressure measurements
did not differ in malaria status, age, or parity, but had a mean
of 70-g (95% conﬁdence interval [CI] [1–150g]) smaller babies
(Table S1). As previously observed, PM was associated with
ﬁrst pregnancy, younger age, and lower birth weight (Table 1).
When women of all ages were analyzed in aggregate, blood
pressure did not differ between PM-positive and PM-negative
women (Table 1), consistent with previous reports. Because
age and parity are independently related to risk of both PM
and hypertension, we examined the effects of age and parity
on the relationship between PM and hypertension (Table 1).
Hypertensive PM-positive women were signiﬁcantly younger
than normotensive PM-positive women, and also had a trend
toward lower parity (Table 1). When hypertension prevalence
was examined over different age strata, PM appeared to
increase the risk of hypertension in younger women, but
decreased the risk in older women (Figure 1). By factorial
ANOVA, the interaction term (age 3 PM) signiﬁcantly
modiﬁed the relationship between PM and hypertension (p
¼ 0.005). The interaction term (parity 3 PM) had a similar
effect that was also signiﬁcant (p ¼ 0.030). When data were
Table 1. Clinical Data for the Women in the Study, Stratified by PM Status and Hypertension
Placental Malaria Hypertension Maternal Age Parity Diastolic Blood Pressure Infant Weight
y np # np mm Hg np kg np
PM (þ) HT and NT 23.3 (5.1) 85 1 (0–1) 85 74.6 (8.6) 85 2.95 (0.41) 77
PM (–) HT and NT 26.6 (6.4) 602 ,0.001 2.00 (0–3) 600 ,0.001 74.8 (8.3) 603 0.846 3.24 (0.42) 552 ,0.001
PM (þ) HT 19.9 (2.1) 11 0 (0–1) 11 90.0 (6.3) 11 2.76 (0.40) 10
NT 23.8 (5.3) 74 0.017 1 (0–1) 74 0.109 72.3 (6.3) 74 n/a 2.98 (0.41) 67 0.104
PM (–) HT 27.8 (6.5) 73 2 (1–5) 73 89.7 (6.0) 73 3.30 (0.43) 67
NT 26.4 (6.3) 529 0.079 2 (0–3) 527 0.090 72.7 (6.2) 530 n/a 3.23 (0.42) 485 0.182
Interaction terms (PM 3 age) 687 0.005 (PM 3 parity) 685 0.030
Data presented as mean (SD), except for parity is presented as median (IQR).
p-Values calculated by unpaired t-test, by Mann-Whitney test for parity, and by ANOVA for the interaction between PM and hypertension.
HT, hypertensive; NT, normotensive.
doi:10.1371/journal.pmed.0030446.t001
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positive women were at signiﬁcantly increased odds of
hypertension compared with PM-negative women for ﬁrst-
time mothers aged 18–20 y (odds ratio [OR] [95% CI] ¼ 3.1
[1.1–9.0], n ¼ 142, p ¼ 0.035), but not older ﬁrst-time mothers
(zero cases, n ¼ 60), or mothers of later pregnancy (OR [95%
CI] ¼ 0.6 [0.2–1.9], n ¼ 483, p ¼ 0.418).
We examined placental pigment deposition and placental
parasite density in PM-positive women to determine whether
chronic forms of PM were associated with hypertension
(Table 2). As previously observed, pigment deposition was
greatest in ﬁrst-time mothers, and was negatively correlated
with birth weight (R ¼  0.525, n ¼ 32, p ¼ 0.002). PM-positive
ﬁrst-time mothers with hypertension had signiﬁcantly in-
creased amounts of pigment compared with PM-positive ﬁrst-
time mothers without hypertension. Hypertension was
associated with low placental parasite density, particularly
in ﬁrst-time mothers. Placental parasite density was nega-
tively associated with diastolic blood pressure (all mothers: R¼
 0.212, p ¼ 0.052, n ¼ 85; ﬁrst-time mothers: R ¼  0.345, p ¼
0.034, n ¼ 38). Thus, hypertension in PM-positive women was
associated with features of chronic disease, such as heavier
pigment deposition and lower parasite density.
We measured sVEGFR1 levels in peripheral plasma by
ELISA (Figure 2A). sVEGFR1 levels in PM-negative normo-
tensive ﬁrst-time mothers were comparable to levels in
healthy ﬁrst-time mothers from non-endemic countries [20].
Compared with uninfected ﬁrst-time mothers, sVEGFR1
levels were signiﬁcantly elevated in ﬁrst-time mothers with
PM or with hypertension, and were non-signiﬁcantly elevated
in those with both. During later pregnancies, sVEGFR1 levels
did not differ with PM. We determined sVEGFR1 transcript
abundance in placental tissue of ﬁrst-time mothers by
quantitative RT-PCR (Figure 2B). Placental transcript levels
correlated with peripheral protein levels (Pearson Rho ¼
0.483, p , 0.001, n ¼ 49), and were signiﬁcantly elevated in
ﬁrst-time mothers with PM, hypertension, or both. sVEGFR1
transcript levels were speciﬁcally elevated in tissue that had
maternal inﬂammatory cells in the intervillous space (Figure
2C).
We explored whether sVEGFR1 expression occurred in
villous trophoblast cells, which are of fetal origin (Figure 3).
In uninfected placentas, VEGFR1 immunoreactivity in villous
trophoblast was not observed. In infected placentas from
ﬁrst-time mothers who were hypertensive or had inﬂamma-
tory inﬁltrates, VEGFR1 immunoreactivity co-localized with
trophoblast, and not with maternal inﬂammatory cells.
Placental transcript levels of VEGF, a ligand for sVEGFR1,
were also signiﬁcantly elevated in ﬁrst-time mothers with PM,
but were not elevated in those with hypertension alone
(Figure 4A). In contrast to the VEGFR1 localization studies,
maternal inﬂammatory cells but not trophoblast cells were
immunoreactive for VEGF in ﬁrst-time mothers with PM
(Figure 4B). VEGF-reactive cells had the morphology of
pigment-containing macrophages (Figure 4C).
Discussion
In this study, PM was associated with hypertension in young
ﬁrst-time mothers with histologic features of chronic disease,
but was not related to hypertension in older or multigravid
women. Similarly, PM was associated with elevated levels of
sVEGFR1 in ﬁrst-time mothers but not in later mothers. In
ﬁrst-time mothers with PM, sVEGFR1 was localized to the
fetal trophoblast and VEGF was localized to maternal
macrophages. Limitations of this study included the absence
of proteinuria data, preventing the differential diagnosis
between preeclampsia and gestational hypertension, and the
lack of longitudinal or interventional data.
We propose a model in which chronic PM during ﬁrst
pregnancies causes hypertension. The effect of chronic PM to
increase blood pressure may be mediated by trophoblast
expression of sVEGFR1. Malaria infection lowers blood
pressure in non-pregnant individuals, and in our study
placental parasite density was negatively associated with
blood pressure in ﬁrst-time mothers. Some ﬁrst-time mothers
with PM and elevated sVEGFR were normotensive, and we
Figure 1. Line Graph Illustrating the Prevalence of Hypertension in PM-
Positive and PM-Negative Women in Different Age Strata
doi:10.1371/journal.pmed.0030446.g001
Table 2. Relationship between Hypertension and Placental Parasite Density and Malarial Pigment in PM-Positive Women
Parity Hypertension Pigment Deposition Parasite Density
Percent of Fields np Percent IE np
First pregnancy HT: 43 (31–61) 7 1.00 (0.83–1.45) 7
NT: 22 (11–34) 27 0.017 4.50 (1.65–9.25) 31 0.026
Later pregnancy HT: 38 1 0.60 (0.30–1.05) 4
NT: 9 (3–25) 33 0.142 1.02 (0.43–2.88) 43 0.275
PM pigment as percent of positive 60X fields (median [IQR]) with p-values calculated by Mann-Whitney tests, and parasite density presented as percent IE (median [IQR]), with p-values
calculated by Student’s t-test (parasite density log (n þ 1) transformed for statistical testing).
doi:10.1371/journal.pmed.0030446.t002
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density may sometimes counteract the hypertensive effects
of sVEGFR1, or, alternatively, that VEGF at high levels in
some women may exceed the binding capacity of sVEGFR1
and prevent hypertension. A hypotensive effect of parasite
density may be mediated directly by the parasite as observed
with dog heartworm [25], or indirectly by host responses such
as elevated nitric oxide levels.
sVEGFR1 levels are proposed to have utility for detecting
preeclampsia. Our data indicate that such a test would be
confounded by PM in malarious areas, because normotensive
ﬁrst-time mothers with PM had the highest sVEGFR1 levels.
However, sVEGFR1 levels may have utility in identifying PM-
positive women in need of treatment, given the low speciﬁcity
(;50%) of peripheral blood smear diagnosis for detecting
PM. Further, we do not know whether the normotensive
women with elevated sVEGFR1 levels would have gone on to
develop hypertension if they had not delivered.
We observed VEGFR1 localization in the trophoblast but
not in the maternal inﬂammatory cells. Trophoblast VEGFR1
expression has been reported [26,27]; however, as a cau-
tionary note, one study suggested that maternal immune cells
contribute to sVEGFR1 levels in preeclampsia [28]. We
observed VEGF expression in maternal macrophages, but
not the villous trophoblast. Macrophages have previously
been reported to be a source of VEGF [29,30].
The role of sVEGFR1 in healthy pregnancy is not known;
however, VEGF administration in one study caused preg-
nancy loss in mice [31]. VEGF induces monocyte activation
and chemotaxis [32–34], which can be blocked experimentally
by sVEGFR1 [34,35]. We speculate that the fetus expresses
sVEGFR1 during PM in an effort to limit the maternal
inﬂammatory response, and therefore increased sVEGFR1
production may be under selective pressure in malaria-
endemic areas, particularly during ﬁrst pregnancies. We
further hypothesize that exposure to P. falciparum malaria
during human history may have contributed to the elevated
sVEGFR1 levels observed in healthy ﬁrst versus second
pregnancies [36], and the increased prevalence of preeclamp-
sia observed among people of African [37–39] or South Asian
[40,41] ancestry, and may also explain why preeclampsia is
primarily a human condition.
Figure 2. sVEGFR1 Expression Levels in PM-Positive and PM-Negative Women
(A) Peripheral plasma sVEGFR1 levels (median [IQR]). Levels are indicated for mothers stratified by parity, PM, and hypertension (HT).
(B and C) Placental sVEGFR1 mRNA abundance (median [IQR]) in first-time mothers. Levels indicate fold-increase over trophoblast-specific cytokeratin 7
(KRT7) mRNA. Women were stratified (B) by PM and hypertension or (C) by PM and intervillous inflammation.
doi:10.1371/journal.pmed.0030446.g002
Figure 3. Immunofluorescence of Placental Cryosections from First-Time Mothers Showing VEGFR1 Extracellular Domain (Green), Trophoblast (Red),
and Nuclear DNA (Blue)
All fields are 200X magnification. Cryosections from (A) PM-negative normotensive pregnancy; (B) PM-positive normotensive pregnancy with intervillous
inflammation; (C) PM-positive hypertensive pregnancy.
doi:10.1371/journal.pmed.0030446.g003
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Hypertension during Placental MalariaIn conclusion, hypertension occurs in young ﬁrst-time
mothers with chronic malaria, and their elevated sVEGFR1
levels suggest they are suffering from preeclampsia. Clinical
studies should address the relationship between peripheral
parasitemia, sVEGFR1 levels, and blood pressure longitudi-
nally over the course of gestation, and should examine the
effects of VEGFR1 gene polymorphisms on these outcomes.
Effective prevention of PM could lower the incidence of
hypertension and should be examined in interventional trials.
Supporting Information
Table S1. Clinical Data for Women Recruited into the MOMS Project,
Stratiﬁed by Whether or Not Blood Pressure Measurements Were
Recorded
Found at doi:10.1371/journal.pmed.0030446.st001 (28 KB DOC).
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Editors’ Summary
Background. Malaria is one of the world’s most serious health problems.
It causes about 1 million deaths every year, and most of these deaths are
in children. Several different parasites can cause malaria; the most
serious is Plasmodium falciparum. One of the most serious consequences
of infection is that this parasite can multiply in the placenta of a
pregnant woman. This ‘‘placental malaria’’ is very harmful to the mother
and to the fetus; it leads to low birth weight and is estimated to be
responsible for the deaths every year of about 200,000 babies within
their first year of life. A woman who is pregnant for the first time is most
likely to suffer from placental malaria, and to have her placenta become
highly infected and extremely inflamed. If she later becomes pregnant
again, she will be protected to some extent by antibodies she has
developed against the parasite.
Another problem that is common in tropical countries and also
causes many deaths during pregnancy is preeclampsia—high blood
pressure (hypertension) and protein loss in the urine. This is also a
condition that is most common in first-time mothers. The causes of
preeclampsia are not clear, but many factors are probably involved.
Among the theories that have been proposed are that inflammation in
the placenta might play a part, and that there may be a ‘‘conflict’’
between the needs of the mother and those of the fetus.
Why Was This Study Done? The researchers wanted to see whether
placental malaria might be a factor in the development of preeclampsia.
This association has been suggested before, but there has been no clear
evidence.
What Did the Researchers Do and Find? Working with pregnant
women in Tanzania, they found that, overall, women with placental
malaria were no more likely than other women to develop hypertension.
However, for those women who were aged 18–20 and pregnant for the
first time, having placental malaria was associated with hypertension.
The researchers also measured levels of a substance called sVEGFR1 (also
called sFlt1), which is known to increase before and during preeclampsia
and is thus considered to be a biomarker for the condition. sVEGFR1
levels were high in first-time mothers with either placental malaria or
hypertension, or both, but levels were not raised in other mothers with
these conditions. A related substance, VEGF, which is known to be
involved with the process that causes inflammation, was high in first-
time mothers with placental malaria, but not in those who had
preeclampsia alone.
What Do These Findings Mean? The researchers believe that their
findings support the view that, in younger first-time mothers only,
placental malaria can cause preeclampsia and that this results from a
conflict between the mother and her fetus. Action to reduce the chance
of such women getting malaria would have the additional benefit of
lowering their chance of developing preeclampsia. The findings have
also led the researchers to propose possible mechanisms as to how
placental malaria leads to preeclampsia. They have made suggestions
regarding the further research that is now needed.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030446.
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